UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer
• •* Progressive, persistent, or recurrent disease
• •Measurable disease outside prior radiotherapy field unless disease progression occurred after radiotherapy
• •Tumor lesions accessible for biopsy
• •* Patients with a medical contraindication to tumor biopsy may be allowed at the discretion of the principal investigator
• •No more than 2 prior chemotherapy regimens
• •* At least 1 regimen must have contained a platinum agent (i.e., carboplatin or cisplatin)
• •No known brain metastases
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-2 OR
• •Karnofsky 60-100%
• •Life expectancy
• •More than 12 weeks
• •Hematopoietic
• •WBC at least 3,000/mm\^3
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hepatic
• •Bilirubin no greater than upper limit of normal (ULN)
• •AST/ALT no greater than 2.5 times ULN
• •Renal
• •Creatinine no greater than ULN OR
• •Creatinine clearance at least 50 mL/min
• •Cardiovascular
• •No history of coronary artery disease
• •No symptomatic cardiac dysfunction
• •No cardiac pathology by electrocardiogram\* NOTE: \*Patients with symptomatic coronary artery disease must undergo an electrocardiogram
• •Pulmonary
• •No symptomatic pulmonary dysfunction
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for at least 8 weeks after study participation
• •No prior allergic reaction attributed to compounds of similar chemical or biological composition to UCN-01 or other study agents
• •No insulin-dependent diabetes mellitus
• •* Diabetes controlled by diet or oral hypoglycemic agents allowed at the discretion of the investigator
• •No other concurrent uncontrolled illness
• •No ongoing or active infection
• •No psychiatric illness or social situation that would preclude study compliance
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •More than 4 weeks since prior biologic therapy and recovered
• •Chemotherapy
• •See Disease Characterisitcs
• •More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• •No prior topotecan
• •No other prior topoisomerase I inhibitors
• •Endocrine therapy
• •More than 4 weeks since prior hormonal therapy and recovered
• •Radiotherapy
• •See Disease Characteristics
• •More than 4 weeks since prior radiotherapy and recovered
• •No prior radiotherapy to more than 40% of bone marrow
• •No prior mediastinal irradiation
• •Surgery
• •More than 4 weeks since prior surgery and recovered
• •Other
• •No other concurrent anticancer therapy
• •No other concurrent investigational agents
• •No concurrent combination antiretroviral therapy for HIV-positive patients